Introduction
Xenotransplantation represents a potential solution to the shortage of human organs and tissues. Humans, however, reject porcine grafts owing to natural xenoantibodies, most of which are directed at the gal epitope (Gala1-3Galb1-4GlcNAc-R). 1 The gal carbohydrate, synthesized by a1,3galactosyltransferase (aGT), is not expressed in humans, apes or Old-World monkeys. 2 Anti-gal antibodies are produced, however, in aGT À/À knockout mice that lack this carbohydrate. [3] [4] [5] Mixed-cell chimerism, achieved following transplantation of aGT À/À knockout mice with wild-type gal + bone marrow (BM), 6, 7 leads to tolerance to gal + heart grafts. The application of gene therapy as a means to achieve tolerance was first reported in aGT À/À knockout mice transplanted with BM, transduced with a murine retrovirus encoding the aGT enzyme. 8 We reported that permanent tolerance to gal + hearts can be achieved in this animal model using lentiviral vectors, 9 and Ogawa et al. 10 reported similar results using transfer of adenovirus-transduced, autologous splenic lymphocytes. More recently, we have shown that aGT-encoding lentivectors can achieve sufficient chimerism in aGT À/À mice to result in permanent tolerance to gal + hearts following sublethal irradiation. 11 The objective of the present study was to apply non-myeloablative conditions and lentiviral vectors to achieve chimerism for the gal epitope in non-human primates, and to study the effect of this procedure on humoral immune responses to porcine cells. This is a key step to clinical applications of a similar ex vivo gene therapy approach for humans.
Results
Juvenile rhesus monkeys (Macaca mulatta) were selected for these studies based on their low, matched serum levels of pre-existing immunoglobulin M (IgM) and immunoglobulin G (IgG) anti-gal antibodies. Anti-gal xenoantibody levels were determined by enzyme-linked immunosorbant assay (ELISA) using gal pentasaccharide-and trisaccharide-coated plates. Autologous total BM and BM-derived CD34 + cells were transduced with a lentivector-expressing porcine aGT, or a control lentivector. The cells were pooled and transplanted 24 h posttotal body irradiation (TBI) using the intravenous route into recipients that had received submyeloablative TBI, but no other immunosuppressive regimens before bone marrow transplantation (BMT). Table 1 summarizes the treatment of each BMT recipient. This method of transduction proved successful in achieving chimerism at levels sufficient to induce tolerance to the gal carbohydrate in our prior studies in aGT À/À knockout mice.
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An aliquot of transduced cells was kept for 4-6 days in culture to test transduction efficiency. [12] [13] [14] Cell-surface gal expression on transduced cells, as monitored by the binding of lectin isolectin B 4 (IB4) to gal carbohydrates, [15] [16] was evaluated by flow cytometry and detected on up to 27% of rhesus monkey BM cells at 4-6 days posttransduction ( Figure 1a) . The presence of the porcine aGT transgene was demonstrated by quantitative polymerase chain rection (qPCR) in the aGT-transduced cells that were transplanted (Figure 1b) . Peripheral blood and BM samples were collected at 8 and 21 days post-transplantation, and regularly for a period of 1 year thereafter, to study the immune profile, cell reconstitution, and the pattern and persistence of engraftment in hematopoietic cell lineages.
An anti-gal IgG1 immune response is induced following transplantation of gal + BM
ELISA experiments were performed on gal pentasaccharide-coated plates to examine changes in the serum anti-gal antibody profiles after transplantation ( Figure 2 ). The levels of anti-gal IgM antibodies did not significantly increase at days 8 and 21 post-BMT (Figure 2a ). However, transplantation of gal + -transduced BM cells did induce an anti-gal IgG response in the recipients, as early as 8 days post-BMT (Figure 2b ). Anti-gal IgG xenoantibodies were not observed in the control BMT animals, which were transplanted with cells that did not express the gal epitope. In all gal + BM recipients (gal + BMT), the anti-gal IgG antibodies were of IgG1 subtype (Figure 2c ). These antibodies were not capable of complementdependent cytotoxicity to pig cells (Figure 2d ). Genomic DNA was extracted from the BM and peripheral blood cells that were harvested post-transplantation. qPCR was used to detect the presence of the aGT transgene. Figure  3 shows that the transgene was detected in the marrow of the gal + BM recipients at 8 days post-BMT.
B-cell numbers decline following sublethal irradiation
Hematopoietic reconstitution was found to be rapid in the animals post-TBI. Examination of peripheral blood mononuclear cell (PBMC) populations by flow cytometry using lineage-specific markers showed a consistent decline in the B-cell population in all treated monkeys. The data for four representative gal + BMT-treated animals and two corresponding controls are shown in Figure 4 . The profiles of the other mononuclear cell lineages examined were unaltered, with some variation from animal to animal. This observation suggests that B cells in rhesus macaques were less resistant to irradiation than other lineages. The decrease ranged from 48 to 92% (n ¼ 7) in the peripheral blood. The depletion was similar in the BM. By day 50 post-BMT, B-cell numbers returned to values that were similar to pre-BMT levels. This Abbreviation: BMT, bone marrow transplantation; TBI, total body irradiation. Inhibition of xenoantibody production using lentiviral vectors JY Fischer-Lougheed et al transient drop in circulating lymphocytes was also observed by others in rhesus monkeys following a 3 Gy TBI. 17 The sensitivity of B cells to submyeloablative irradiation has been reported in mice, 18 and observed in aGT À/À knockout mice; 11 however, it has been suggested that B cells producing natural anti-gal antibodies in aGT À/À mice are irradiation resistant. 6 Long-term, low-level chimerism can be achieved in rhesus monkeys
Cell-surface gal-expressing cells were examined in the peripheral blood and BM of gal + BM recipients by flow cytometry. The levels of total gal + cells peaked between 8
and 22 days post-transplantation, then declined after 10 weeks to low levels that ranged between 1 and 8% of PBMCs over the course of the experiment. Similar levels of expression were detected in the BM. Chimerism was confirmed by qPCR (see Figure 3 ). Dual-color flow cytometry was used to identify which cell lineages expressed the gal carbohydrate in the aGT BMT chimeras (shown in Figure 5 for three representative gal + BM recipients). Gal carbohydrate surface expression was observed on B cells (CD20 Examination of the levels of anti-pig IgM antibodies (Figure 7c ), measured by ELISA on plates coated with porcine aortic endothelial cells (PAECs), showed no significant difference in the response of gal + BMT animals and controls, suggesting that the reduced cytotoxicity 21 in gal + BMT monkeys was owing to the attenuated production of antibodies directed at the gal carbohydrate epitope. The persistence of low levels of gal + -transduced cells, therefore, was sufficient to inhibit production of anti-gal antibodies. The immune response to non-gal xenoantigens remained intact.
Discussion
The use of rhesus monkeys to determine whether gene therapy can induce tolerance to porcine xenografts represents an important pre-clinical model, as these animals are most closely related to humans that have pre-existing xenoantibodies that initiate xenograft rejection. 2, 21, 22 We show here that transplantation of autologous, transduced marrow expressing cell-surface gal carbohydrate can attenuate the production of anti-gal IgM antibodies, even after challenge with porcine Inhibition of xenoantibody production using lentiviral vectors JY Fischer-Lougheed et al hepatocytes. IgM antibodies to other porcine xenoantigens were produced at similar levels in the gal + BM recipients as in controls. Specific tolerance to the gal carbohydrate is considerably more difficult to achieve in monkeys compared with aGT À/À knockout mice owing to the presence of memory cells and pre-existing xenoantibodies in non-human primates. High levels of gal expression in the engrafted BM and low levels of pre-existing cytotoxic xenoantibodies are minimal requirements for the success of the procedure. The transplantation of autologous, aGT-transduced cells induced an IgG1 antibody response in the gal + recipients. These antibodies were not capable of complementdependent cytotoxicity to pig cells. In the aGT À/À knockout mice, the observation that long-term chimerism could be achieved in the presence of high levels of anti-gal IgG1, predating transplantation of gal + BM, led the authors to suggest that IgG1 antibodies may have an inhibitory effect on anti-gal-mediated marrow rejection. 7 Our data in rhesus monkeys are consistent with the concept that IgG1 anti-gal antibodies are not harmful to engraftment of gal + cells. Several types of vectors and conditions have been assayed for gene transfer in non-human primate hematopoietic stem and progenitor cells. [22] [23] [24] [25] [26] [27] These studies indicate that the maintenance of transgene expression depends on the dose of irradiation, and hence the space for engraftment, the repopulating capacity of the transduced progenitor cells and the immunogenicity of the transgene. In low-dose-irradiated rhesus monkeys transplanted with high numbers of CD34 + cells transduced with a retrovirus expressing murine CD24, transgene expression was detected in 10-15% of peripheral blood leukocytes for over 4 months, and then declined thereafter. 28 These animals did not appear to develop an immune response to the product of the Inhibition of xenoantibody production using lentiviral vectors JY Fischer-Lougheed et al introduced gene. 29 The gene transfer efficiency we report here with lentivectors is similar. Lentivectors, however, offer several advantages as gene transfer vehicles. They efficiently transduce quiescent progenitors and nondividing cells, thus reducing the time in ex vivo culture and the risk of losing multipotency. Recent studies also suggest that lentivectors integrate more randomly in the recipient's genome when compared with retroviral vectors. 30 A careful analysis of vector integrating sites has become the focus of studies in numerous laboratories owing to the fact that preferential integration into specific sites has imposed a safety concern in vectors designed for clinical use. 31, 32 It is therefore important that vectors are designed and selected for both optimal function and safety. Testing in pre-clinical, non-human primate models is therefore an important pre-requisite for understanding the long-term consequences of gene therapy procedures in a clinically relevant model of transplantation.
Our experimental procedure for transduction is novel in which we transplanted a pool of total BM transduced with low multiplicity of infection (MOI) and fractionated CD34 + cells transduced at high MOI (75-100). Transduction at high MOI has been shown to over ride cellular factors that inhibit efficient transduction of rhesus cells with HIV-1-based vectors. [12] [13] [14] High levels of chimerism were initially observed in all monkeys, then subsequently dropped to low but detectable levels for a period of 1 year post-transplantation. This may have resulted from insufficient transgene integration into the pluripotent hematopoietic progenitor cells, vector silencing or lack of a selective advantage for the transduced cells. Other groups have studied CD34 + hematopoietic progenitor cell-mediated gene transfer using HIV-1-derived constructs to express enhanced green fluorescence protein (EGFP) in non-human primates, and have obtained sustained low transgene marking in recipient baboons, 25 and rhesus macaques (0.5-8% EGFP in certain lineages up to 4 years post-transplantation; An et al. 23 and Kung et al.
27
). Unlike the animals in those studies, our recipients were not subjected to myeloablative irradiation, which would enhance selection for transduced autologous marrow engraftment. Although tissuespecific tolerance has been achieved using lentiviral vectors following 10 Gy of irradiation, and following 500-650 cGy of irradiation using retroviral vectors, this paper represents the first demonstration that similar results can be achieved following 300-350 cGy of TBI.
Given their potential as vehicles for gene therapy, lentiviral vectors are undergoing continuous remodeling to improve stable and safe transgene integration and expression in stem cells. [33] [34] [35] [36] [37] We elected to use SIVderived lentiviral vectors for this study based on reports that they are more efficient for transduction of simian stem cells. 19, 20, [38] [39] [40] Our results using SIV-based aGT constructs are consistent with those findings. Under nonmyeloablative conditions, however, we were not able to achieve the levels of engraftment reported by Hanawa et al. 19 using an SIV-based EGFP-expressing vector (marking up to 14% of CD3 + and 17% CD20 + cells 7 months after transfer). One significant difference is that their animals received larger doses of efficiently transduced CD34
+ cells (7-20 Â 10 6 cells/kg) following myeloablative pre-conditioning. We elected to apply a nonmyeloablative regimen for our studies, as this procedure is more appropriate for clinical applications in humans. Our group has recently shown that lentiviral vectors can be used to achieve chimerism and tolerance following 300 cGy of irradiation in the aGT À/À knockout mouse model for xenotransplantation. 11 This paper extends this study to a clinically applicable non-human primate model in which we have demonstrated that the level and kinetics of chimerism that can be achieved in monkeys using these vectors is strikingly similar to the levels of chimerism in mice that we have recently reported to be sufficient for tolerance induction. This raises the exciting possibility that this regimen may be useful in the development of procedures to induce transplantation tolerance in large animal models in the future. Inhibition of xenoantibody production using lentiviral vectors JY Fischer-Lougheed et al
Materials and methods

Animals
All animal procedures conformed to the requirements of the Animal Welfare Act, and protocols were approved before implementation by the Institutional Animal Care and Use Committee at the University of California, Davis. Sixteen juvenile rhesus monkeys (M. mulatta) ranging in age from 7.5 to 23 months and weights of 1.5-2.7 kg were screened for pre-existing anti-gal xenoantibodies. Seven animals with matched levels of xenoantibodies were selected for BMT for these studies (five experimental and two controls). Their peripheral blood cells were gal negative, as demonstrated by flow cytometry with fluorescence isothiocyanate (FITC)-lectin IB4 (from Bandieraea simplicifolia, Sigma, St Louis, MO, USA) that binds to gal epitopes. 16 Serum, blood and BM samples from four rhesus monkeys that did not receive a control or gal + BM transplant provided additional controls for this study.
Cell isolation, CD34
+ cell enrichment and transduction
Autologous BM was harvested and mononuclear cells were isolated by Ficoll-Histopaque (Sigma, USA) density centrifugation. CD34 + cells were enriched from half of the BM, using mouse anti-human-CD34 antibody 12.8 (kind gift from RG Andrews, Fred Hutchinson CRC, Seattle, WA, USA) and anti-mouse IgM-micromagnetic beads (Milltenyi Biotec, Auburn, CA, USA). Purity was assessed by flow cytometry using R-phycoerythrin (PE)-conjugated anti-CD34 antibody (BD Pharmingen, San Diego, CA, USA). The remainder of the BM aspirate (total BM) was transduced without CD34 + cell enrichment. For two animals (nos. 296 and 318), BM aspirates had been collected over several weeks before transplantation and cryopreserved, in order to increase the amount of available cells for transfer. These cells were placed in culture 24 h before transduction. Cells were seeded on RetroNectin-coated (Takara, Japan) plates and transduced with lentivector aGT (pCSO-rre-cppt-MCU3-a1,3gal-WPRE) or a control lentivector (aGT in reverse orientation). 9 The cells were plated at 4 Â 10 6 cells/well and transduced in 0.5 ml of X-VIVO15 (BioWhittaker, Walkersville, MD, USA) supplemented with 100 ng/ml each of human cytokines interleukin (IL)-3, stem cell factor, Flt3-ligand and TPO (BioSource, Camarillo, CA, USA) and IL-6 (Stem Cell Technologies, Canada). The MOI ranged from 75 to 100 for CD34 + cells, and 8-15 for total BM. Cells were exposed to the lentiviral vector twice in 16 h. The same procedure was used to prepare and transduce the cells with a SIV-derived aGT lentivector (pSIV-SIN-MNDU3-a1,3gal), pseudotyped with vesicular stomatitis virus-glycoprotein. The latter vector was constructed at the CHLA vector core using an SIV-parent vector derived from SIVmac251 and obtained from FL Cosset (LVRTG, INSERM U412, Ecole Normale Supérieure de Lyon, France). 38, 41 The MOI range for SIV vector transduction was 3 for total BM and 15-25 for the CD34 + fractions.
BMT and immunization
Twenty-four hours after BM aspiration, the transduced cells (CD34 + cells and total BM) were pooled, and injected intravenously into recipients that had previously received submyeloablative irradiation of a 300 cGy (split into two doses over 24 h) or a single dose of 350 cGy on the day of transplantation (see Table 1 ). No additional immunosuppressive treatment was given. Monkeys nos. 240 and 796 were challenged at 3 and 5 months post-BMT with a subcutaneous injection of 60 million hepatocytes and endothelial cells (kind gift from Ronald Faris at MultiCell Technologies Inc., Warwick, RI, USA). Monkeys nos. 322, 296 and 318 were challenged with porcine cells at 2 and 3 months post-BMT, and monkeys nos. 309 and 256 were challenged at 4 months post-BMT. The porcine cell preparation used for immunization has been shown to induce a robust anti-pig antibody response in rhesus macaque controls. 42 Serum from these animals obtained pre-and post-immunization with an identical number of cells provided additional control samples for this study.
Hematopoietic cell reconstitution and molecular chimerism BM and peripheral blood samples were collected regularly. Complete blood counts were analyzed each time a blood sample was collected. Hematopoietic cell reconstitution and gal expression were analyzed by dual-color flow cytometry, performed on a FACScalibur cytometer using CellQuest software (Becton Dickinson, San Jose, CA, USA). Labels were FITC-lectin IB4 (Sigma, USA), and PE-conjugated mouse antibodies anti-CD3, anti-CD11b, anti-CD20, anti-CD14, anti-CD56 and anti-CD16 (BD Pharmingen, USA). Human AB,Rh À serum was used at 2% to block nonspecific binding to Fc receptors. The values reported for detecting transduced cells (chimerism) were determined conservatively by setting the gates to exclude nonspecific binding to control animals (this includes animals transplanted with BM transduced with the control vector). Background labeling was determined using cells from control animals for each experiment and was subtracted from the lectin binding in gal + BMT animals to determine the levels of chimerism. Owing to the very conservative manner in which we have calculated chimerism, our quantitative assessment of gal + cells provided may be an under-representation of labeled cells in these animals.
qPCR analysis
Real-time qPCR was used to detect the porcine aGT transgene in DNA isolated from transduced BM samples kept 4-6 days in culture, as well as from BM and peripheral blood samples of BMT recipients at various time points post-transplantation. qPCR was performed using the ABI PRISM 7700 Sequence Detector and analyzed using SDS1.9.1 software (Applied Biosystems Inc., Foster City, CA, USA). For each sample, the data were normalized to the signal obtained for the rhesus housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene (ratio method as detailed in the Quantitect SYBR Green Handbook). A control standard curve for GAPDH was generated using serial dilutions (copies/ml) of a control GAPDH DNA. Briefly, a GAPDH gene fragment was cloned into the pCR2.1 cloning vector (Invitrogen, Carlsbad, CA, USA) and linearized, the DNA concentration was determined by spectophotometry, confirmed by gel electrophoresis and the number of copies for the standard was calculated as described in the SYBR Green Handbook protocols (Qiagen, Valencia, CA, Inhibition of xenoantibody production using lentiviral vectors JY Fischer-Lougheed et al USA). Samples were run in duplicate and included a negative control (deionized water), a standard curve for GAPDH and monkey cell DNA prepared from the peripheral blood and BM taken at various times after BMT. Both GAPDH and aGT primers were used to amplify DNA within each of the experimental samples. The oligonucleotide primers (Operon Biotechnologies Inc., Alameda, CA, USA) used for the qPCR assay were: GAPDH reverse, 5 0 -TGCACCACCAACTGCTTAGC-3 0 and forward, 5 0 -GGCGTGGACTGTGGTCATGAG-3 0 ; porcine aGT reverse, 5
0 -CCAAAACACAACCATTACAG TTGAG-3 0 and forward (within the MCU3 region of the lentivector), 5 0 -GTTCGCTTCTCGCTTCTGTT-3 0 . Quantitative amplifications were performed using 1 mg of DNA and the Quantitect SYBR Green PCR kit (Qiagen, USA) according to the manufacturer's protocol. The PCR conditions were: 951C 15 min; 45 cycles (951C 15 s; 561C 30 s; 721C 30 s). Data are presented as relative amounts, standardized to GAPDH.
Enzyme-linked immunosorbant assays
Anti-gal IgM and IgG serum levels were measured by ELISA, as described previously, 9 using purified gal carbohydrates in tri-and pentasaccharide forms (V-Labs, Covington, LA, USA) or PAECs as targets. Peroxidaseconjugated anti-human IgM and IgG antibodies were obtained from Jackson ImmunoResearch Labs and Sigma, respectively. IgG subtyping was performed using peroxidase-conjugated anti-human IgG antibodies (The Binding Site Inc., San Diego, CA, USA). 43 Total IgM and IgG serum levels were measured using human IgM and IgG ELISA quantitation kits (Bethyl Laboratories, Montgomery, TX, USA), according to the manufacturer's instructions. The peroxidase substrate was SureBlue TMB (KPL, Gaithersburg, MD, USA).
Antibody-mediated cytotoxicity
Levels of xenoantibodies capable of complement-dependent cytotoxicity were measured by a flow-cytometric toxicity assay. 44 Minipig kidney cells (ATCC, Manasses, VA, USA) or PAEC were incubated at room temperature 45-60 min with heat-inactivated serum samples diluted 10-fold, and then 60 min with Low-Tox M Rabbit Complement (Cedarlane, Hornby, ON, Canada). Cell death was evaluated by propidium iodide uptake, measured using a FACSCalibur cytometer (Becton Dickinson, USA).
Statistical analysis
The results were analyzed by Student's t-test. Po0.0507 was assessed as significant. All data are shown as mean7s.e.
